Nyrada (ASX:NYR) submitted its phase IA first-in-healthy human volunteer clinical trial regulatory package of drug candidate NYR-BI03 for Human Research Ethics Committee review, according to a Tuesday filing with the Australian bourse.
The biotechnology company is developing NYR-BI03 for the potential treatment of stroke and traumatic brain injury, the filing said.
The review, scheduled for January 2025, will allow for the start of volunteer recruitment for the trial, according to the filing.
Shares rose past 2% in afternoon trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.